NASDAQ:PRNBPrincipia Biopharma Stock Price, Forecast & News

Principia Biopharma's stock was trading at $53.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRNB stock has increased by 18.6% and is now trading at $63.89. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Principia Biopharma.

Principia Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Principia Biopharma.

Principia Biopharma Inc (NASDAQ:PRNB) issued its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.99) EPS for the quarter, missing the Zacks' consensus estimate of ($0.79) by $0.20. View Principia Biopharma's earnings history.

5 Wall Street analysts have issued 12 month price targets for Principia Biopharma's shares. Their forecasts range from $76.00 to $82.00. On average, they anticipate Principia Biopharma's share price to reach $78.60 in the next twelve months. This suggests a possible upside of 23.0% from the stock's current price. View analysts' price targets for Principia Biopharma.

Media headlines about PRNB stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Principia Biopharma earned a news sentiment score of -3.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutPrincipia Biopharma.

Some companies that are related to Principia Biopharma include Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE) and Evotec (EVTCY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include AbbVie (ABBV), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Corbus Pharmaceuticals (CRBP) and Five Prime Therapeutics (FPRX).

(PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

Principia Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (6.84%), Cormorant Asset Management LP (6.36%), BlackRock Inc. (5.93%), Wellington Management Group LLP (4.87%), State Street Corp (1.98%) and Pictet Asset Management Ltd. (1.37%). Company insiders that own Principia Biopharma stock include Alan Colowick, Christopher Y Chai, Daniel J Becker, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Orbimed Advisors Llc, Plc Glaxosmithkline, Roy C Hardiman, Simeon George, Srinivas Akkaraju and Stefani Wolff. View institutional ownership trends for Principia Biopharma.

PRNB stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Redmile Group LLC, Nuveen Asset Management LLC, Pictet Asset Management Ltd., Massachusetts Financial Services Co. MA, JPMorgan Chase & Co., Alliancebernstein L.P., and AXA. Company insiders that have sold Principia Biopharma company stock in the last year include Alan Colowick, Christopher Y Chai, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Roy C Hardiman, and Stefani Wolff. View insider buying and selling activity for Principia Biopharma.

PRNB stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Cormorant Asset Management LP, BlackRock Inc., Aviva PLC, First Trust Advisors LP, State Street Corp, Grantham Mayo Van Otterloo & Co. LLC, and Two Sigma Investments LP. Company insiders that have bought Principia Biopharma stock in the last two years include Daniel J Becker, Leaf Ventures Ii LP New, Plc Glaxosmithkline, Simeon George, and Srinivas Akkaraju. View insider buying and selling activity for Principia Biopharma.

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRNB stock can currently be purchased for approximately $63.89.

Principia Biopharma has a market capitalization of $2.11 billion and generates $35.16 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.

The official website for Principia Biopharma is www.principiabio.com.

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]